The UK government and the life science industries have marked a year of action and progress for the Office for Life Sciences (OLS) with the release of a final report on its work to date and future...
We’re all familiar with the pressures piling up on healthcare systems around the world. People are living longer and diseases of ageing, such as dementia, are becoming more prevalent. Some illnesses...
The paradox of US legislation relating to the medical use of cannabis, whereby some use of the drug for medical purposes is legally recognised in certain states but completely prohibited by federal...
Yesterday's raids on the premises of several pharmaceutical companies show that the European competition authorities are serious about taking action against suspected anticompetitive behaviour in the...
What’s the best strategy to adopt when seeking US Food and Drug Administration approval for a new pharmaceutical product? In these straitened times, can companies justify going beyond the basic...
Once there was a clear distinction between the scientific evaluation of new drugs and the assessment of their value for use in reimbursement decisions. The latter was often referred to as the “fourth...
On 14 September, Europe's Innovative Medicines Initiative, which aims to find ways of streamlining the drug development process, will hold a press conference to present its achievements to date....
The $2.3 billion fine against Pfizer announced last week 1 is expected to lead to far greater oversight of the way prescription drugs are marketed in the US. The record-breaking fine was a punishment...
It looks as if the breach between European parliamentarians (MEPs) and member state ministers over a proposal to improve the provision of drug information to patients is growing ever wider. Despite...
One of the cornerstones of US President Barack Obama’s healthcare reform plans is a commitment to comparative effectiveness research. “Comparative effectiveness research provides information on the...
Germany’s insistence on finding a consensus on embryonic stem cell research and its ban on the use of home-grown cell lines are hampering its ability to keep pace with other high-technology countries...
The final report of the pharmaceutical sector enquiry was published earlier this month 1 and has been welcomed by both the originator and generic medicines industries. What’s more, both sides are...
The final report on the European Commission’s pharmaceutical sector enquiry has now been published and has reiterated many of the criticisms against the originator industry that were initially raised...
Roche's decision not to rejoin the UK industry body the ABPI after its six-month suspension for breaching the advertising code of practice has understandably made waves in the sector. After all,...
